- Summit has less than a year of cash runway left as PD-1/VEGF verdict nearsSummit’s star asset is the PD-1/VEGF bispecific ivonescimab, which this week produced promising survival data from a late-stage global trial in non-small cell lung cancer. The FDA review is ongoing…BioSpace · 4d ago↗ source
- Roche cans one Carmot obesity asset as another shows best-in-class potentialAcmopatide met the main goal of a Phase 2 study in type 1 diabetes, but Roche is axing the investigational drug to prioritize enicepatide for weight loss, type 2 diabetes and cardiovascular outcome…BioSpace · 4d ago↗ source
- Merck stages expanded access to monthly HIV PrEP pill ahead of approvalFollowing in the footsteps of Gilead, Merck has signed voluntary licensing agreements to enable access to its investigational HIV PrEP pill alimatravir ahead of any regulatory submissions.